Literature DB >> 2685356

The secretory core protein of human hepatitis B virus is expressed on the cell surface.

H J Schlicht1, H Schaller.   

Abstract

Human hepatitis B virus (HBV) causes acute and chronic liver disease, which can result in tumor formation. An as yet unexplained phenomenon is that virus elimination usually correlates with the development of antibodies directed against the HBeAg, a secretory HBV core gene product which can be detected in the serum of infected patients. Expression of HBeAg in a human hepatoma cell line by using recombinant vaccinia viruses revealed that the HBeAg is not only secreted from HBeAg-producing cells but also incorporated into the outer cell membrane. No membrane-expressed core gene product could be detected when the cytoplasmic core protein (HBcAg) was expressed. Immune sera from patients who developed anti-HBe antibodies efficiently recognized the membrane-bound HBeAg, suggesting that surface-expressed HBeAg can serve as a target for an antibody-mediated elimination of HBV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685356      PMCID: PMC251207     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus.

Authors:  J Salfeld; E Pfaff; M Noah; H Schaller
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens.

Authors:  P J Bjorkman; M A Saper; B Samraoui; W S Bennett; J L Strominger; D C Wiley
Journal:  Nature       Date:  1987 Oct 8-14       Impact factor: 49.962

3.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

4.  Formation of transmembraneous hepatitis B e-antigen by cotranslational in vitro processing of the viral precore protein.

Authors:  V Bruss; W H Gerlich
Journal:  Virology       Date:  1988-04       Impact factor: 3.616

5.  The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation.

Authors:  H J Schlicht; J Salfeld; H Schaller
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

6.  A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes.

Authors:  D N Standring; J H Ou; F R Masiarz; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Viral proteins expressed on the surface of murine leukemia cells.

Authors:  J Ledbetter; R C Nowinski; S Emery
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

8.  gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms.

Authors:  S A Edwards; H Fan
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

9.  Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen.

Authors:  O Jean-Jean; M Levrero; H Will; M Perricaudet; J M Rossignol
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

10.  Targeting of the hepatitis B virus precore protein to the endoplasmic reticulum membrane: after signal peptide cleavage translocation can be aborted and the product released into the cytoplasm.

Authors:  P D Garcia; J H Ou; W J Rutter; P Walter
Journal:  J Cell Biol       Date:  1988-04       Impact factor: 10.539

View more
  36 in total

1.  Phylogenetic origin of hepatitis B virus strains with precore C-1858 variant.

Authors:  E Alestig; C Hannoun; P Horal; M Lindh
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

2.  Biosynthesis of the secretory core protein of duck hepatitis B virus: intracellular transport, proteolytic processing, and membrane expression of the precore protein.

Authors:  H J Schlicht
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Hepatitis B virus p25 precore protein accumulates in Xenopus oocytes as an untranslocated phosphoprotein with an uncleaved signal peptide.

Authors:  S Q Yang; M Walter; D N Standring
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein.

Authors:  F Birnbaum; M Nassal
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  Localization of hepatitis B virus core protein and viral DNA at the nuclear membrane.

Authors:  C T Bock; S Schwinn; C H Schröder; I Velhagen; H Zentgraf
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

7.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Hepatitis C virus mutation affects proteasomal epitope processing.

Authors:  Ulrike Seifert; Heike Liermann; Vito Racanelli; Anne Halenius; Manfred Wiese; Heiner Wedemeyer; Thomas Ruppert; Kay Rispeter; Peter Henklein; Alice Sijts; Hartmut Hengel; Peter-M Kloetzel; Barbara Rehermann
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal.

Authors:  A S Lok; U Akarca; S Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

Review 10.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.